The New Frontier of Combination Therapy for IBD: The VEGA RCT
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Bharati Kochar, MD, MS discuss “Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial,” by Feagan BG, Sands BE, Sandborn WJ, et al. Lancet Gastroenterol Hepatol. 2023; 8: 307-20.